CDSCO Panel Accepts Mylan's Post-Marketing Surveillance Report for Liposomal Amphotericin B Injection
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended to accept the Mylan Pharmaceutical's Post Marketing Surveillance study report of Liposomal Amphotericin B for Injection 50mg.
This came after the firm presented the Post Marketing Surveillance study report for the study no. GS-US-131-6403 version no.1.0 dated 23.09.2024 of Liposomal Amphotericin B for Injection 50mg/vial before the committee.
Amphotericin B is a broad-spectrum antifungal medication used to treat serious fungal infections and leishmaniasis. It's considered a "gold standard" antifungal drug and is particularly effective for treating severe systemic fungal infections.
Amphotericin B exerts its antifungal effect by disruption of fungal cell wall synthesis because of its ability to bind to sterols, primarily ergosterol, which leads to the formation of pores that allow leakage of cellular components. This affinity may also account for its toxic effects against select mammalian cells.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.